Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

NCT05683496 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: lonigutamab
DRUG: Placebo

Sponsor

ACELYRIN Inc.